摘要
Abstract
Objective:To explore the clinical efficacy of camrelizumab combined with pemetrexed and platinum-based therapy in the treatment of patients with advanced non-squamous non-small cell lung cancer(NSCLC).Methods:A total of 63 patients with advanced non-squamous NSCLC admitted to a hospital from January 2021 to January 2024 were retrospectively selected and divided into the control group(n=33)and the observation group(n=30)according to the treatment regimen.The control group was treated with pemetrexed disodium for injection combined with cisplatin for injection or carboplatin for injection,while the observation group received additional camrelizumab for injection on the basis of the control group's treatment.Levels of tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)],immune function indicators(CD4+,CD3+,CD8+,CD4+/CD8+),clinical efficacy,adverse events and progression-free survival were compared between the two groups.Results:After treatment,serum levels of CEA,CA125 and CYFRA21-1 were decreased in both groups(P<0.05),with lower levels in the observation group(P<0.05).CD3+,CD4+and CD4+/CD8+were decreased in both groups(P<0.05),but the observation group showed higher levels than the control group(P<0.05).There was no statistically significant difference in CD8+between the two groups of patients after treatment(P>0.05).The disease control rate in the observation group(86.67%)was higher than that in the control group(63.64%,P<0.05).There were no statistically significant differences in the incidences of gastrointestinal toxicity,liver function impairment,thrombocytopenia and hypothyroidism of all grades between the two groups(P>0.05).The incidence of grade 1 reactive capillary hyperplasia in the observation group was higher than that in the control group(P<0.05).The progression-free survival time in the observation group was longer than that in the control group(Log-rank χ²=19.302,P<0.001).Conclusion:Camrelizumab combined with pemetrexed and platinum shows good clinical efficacy in treating advanced non-squamous NSCLC,effectively reducing serum tumor marker levels,improving immune function and prognosis,with favorable safety.关键词
卡瑞利珠单抗/培美曲塞/非小细胞肺癌/晚期/免疫功能/血清肿瘤标志物Key words
carilizumab/pemetrexed/non-small cell lung cancer/advanced/immune function/serum tumor markers分类
医药卫生
